Live Feeds

Source map — Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Every domain this feed has drawn corroborated signal from. We store facts and short excerpts and link back to originals — never republished article bodies.

SourceTypeTrust
The Guardian news 60%
Scientific American news 60%
Eli Lilly news 60%
Reuters news 60%
WSJ news 60%
CNBC news 60%
BioPharma Dive news 60%
ScienceAlert news 60%
Medscape news 60%
Simply Wall Street news 60%
www.biospace.com news 50%
onthepen.substack.com news 50%
www.thebionews.net news 50%
peptidedosages.com news 50%
www.kalios.health news 50%
remyresearch.com news 50%
www.onedayadvisor.com news 50%
pharmaphorum.com news 50%
onthepen.com news 50%
www.europesays.com news 50%
www.archyde.com news 50%
www.biotech-now.co.uk news 50%
patientdaily.com news 50%
www.timeslive.co.za news 50%
pacifictribune.com news 50%
www.clinicalnutritioncenter.com news 50%
www.medicalnewstoday.com news 50%
omniatelehealth.com news 50%
sugarisadrug.com news 50%
dispatchtimes.com news 50%
dictionary.cambridge.org news 50%
www.vocabulary.com news 50%
usdictionary.com news 50%
www.youtube.com news 50%
www.cnbc.com news 50%
www.fool.com news 50%
longbridge.com news 50%
biotech-insider.com news 50%
www.lqventures.com news 50%
medicalxpress.com news 50%
rocketnews.com news 50%
www.beinghealthy.news news 50%
www.glp1authority.com news 50%
www.onedaymd.com news 50%
finance.yahoo.com news 50%
business-gurus.com news 50%
glpobesitymindset.substack.com news 50%